BioCentury | Jan 28, 2020
Company News

Quenching the flames of inflammatory cell death

...Caspase-1; GSDMD - Gasdermin D; IL-1β - Interleukin-1 beta; IL-18 - Interleukin-18; NLRC4 - NRL...
...Absent in melanoma 2 GSDMD - Gasdermin D IL-1β - Interleukin-1 beta NLR-C4 - NRL...
BioCentury | Apr 12, 2019
Product Development

NLRP3 early and often

...NALP10) NLR family pyrin domain containing 3 (NLRP3) (NALP3) (CIAS1) NLR family pyrin domain containing 6 (NLRP6) (NALP6) NRL...
BioCentury | Aug 15, 2018
Preclinical News

Gene transfer regenerates rod cells, restores light sensitivity in blind mice

...transcription factors responsible for retinal development -- orthodenticle homeobox 2 (OTX2), cone-rod homeobox (CRX) and neural retina leucine zipper (NRL)...
...is looking to partner or license the IP. Mark Zipkin Icahn School of Medicine at Mount Sinai Beta-catenin (CTNNB1) Neural retina leucine zipper (NRL) CRX OTX2...
BioCentury | Mar 16, 2017
Translation in Brief

Clearer, CRISPR vision

...A study from NIH’s National Eye Institute (NEI) exploits a new target in the disease, NRL...
...team led by Zhijian Wu, head of NEI’s Ocular Gene Therapy Core, showed that disrupting neural retina leucine zipper (NRL)...
...enhancing survival of the modified rods and preventing cone die-off. The team homed in on NRL...
BioCentury | Mar 15, 2017
Distillery Therapeutics

Ophthalmic disease

...INDICATION: Retinitis Mouse studies suggest inhibiting NRL expression in photoreceptors using CRISPR/ Cas9 could help treat...
...CRISPR/ Cas9 could help treat retinitis pigmentosa. In healthy mice, subretinal injection of CRISPR/Cas9 targeting NRL...
...for daylight vision. In three different genetic mouse models of retinitis pigmentosa, subretinal injection of NRL-targeted...
BioCentury | Nov 16, 2015
Clinical News

IL-18BP: Compassionate use program data

...a 3-month old girl with macrophage activation syndrome due to a genetic mutation of the NRL...
BioCentury | Dec 11, 2014
Distillery Techniques

Technology: Markers

...Approach Summary Licensing status Publication and contact information Markers Mutant NRL family CARD domain containing 4...
BioCentury | Dec 11, 2014
Distillery Therapeutics

Indication: Infectious disease

...Licensing status Publication and contact information Infectious disease Rotavirus IL-18; IL-22; toll-like receptor 5 (TLR5); NRL...
BioCentury | Mar 10, 2014
Company News

Biotie Therapeutics Corp., Neurelis deal

...said it conducted further manufacturing and preclinical work with Neurelis' NRL-1 last quarter and concluded NRL-1's...
...until the start of pivotal pharmacokinetic trials of NRL-1, but no later than Dec. 3. NRL-1...
BioCentury | Oct 7, 2013
Company News

Biotie neurology, hepatic news

...for an exclusive option to acquire Neurelis Inc. (Encinitas, Calif.). Biotie believes Neurelis' lead product NRL-1...
...commercial opportunity in the U.S. that could be accessed via a small, specialist sales force." NRL-1...
Items per page:
1 - 10 of 23